• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·TARSONS.NS
Share

Tarsons Products Limited Stocks

₹ 300Last Updated 23.10.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

₹ 185.56M

₹ 300
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features disposable plastic labware, centrifuge and cryogenic equipment, liquid handling systems, and safety products. Its comprehensive catalog further encompasses items such as bottles, carboys, measuring cylinders, cell culture products, electrophoresis apparatus, microscopy and microbiology tools, vacuum desiccators, mini coolers, cryo boxes, beakers, test tube racks, pipette tips, petri dishes, centrifuge tubes, cryogenic and storage vials, Pasteur pipettes, and vortex mixers, among many others. These offerings are vital for research and applications across various scientific disciplines including molecular biology, cell culture, genomics, proteomics, and immunology.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds ramp up bets against euro to highest level since 2020

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026